These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 18850500)

  • 1. Levetiracetam for the treatment of co-occurring alcohol dependence and anxiety: case series and review.
    Mariani JJ; Levin FR
    Am J Drug Alcohol Abuse; 2008; 34(6):683-91. PubMed ID: 18850500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients.
    Fertig JB; Ryan ML; Falk DE; Litten RZ; Mattson ME; Ransom J; Rickman WJ; Scott C; Ciraulo D; Green AI; Tiouririne NA; Johnson B; Pettinati H; Strain EC; Devine E; Brunette MF; Kampman K; A Tompkins D; Stout R;
    Alcohol Clin Exp Res; 2012 Aug; 36(8):1421-30. PubMed ID: 22324516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of levetiracetam on alcohol consumption in alcohol-dependent subjects: an open label study.
    Sarid-Segal O; Piechniczek-Buczek J; Knapp C; Afshar M; Devine E; Sickles L; Uwodukunda E; Richambault C; Koplow J; Ciraulo D
    Am J Drug Alcohol Abuse; 2008; 34(4):441-7. PubMed ID: 18584574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coadministration of disulfiram and lorazepam in the treatment of alcohol dependence and co-occurring anxiety disorder: an open-label pilot study.
    Bogenschutz MP; Bhatt S; Bohan J; Foster B; Romo P; Wilcox CE; Tonigan JS
    Am J Drug Alcohol Abuse; 2016 Sep; 42(5):490-499. PubMed ID: 27184605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label pilot study of icariin for co-morbid bipolar and alcohol use disorder.
    Xiao H; Wignall N; Brown ES
    Am J Drug Alcohol Abuse; 2016 Mar; 42(2):162-7. PubMed ID: 26809351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers.
    Mitchell JM; Grossman LE; Coker AR; Messing RO
    J Clin Psychopharmacol; 2012 Apr; 32(2):269-72. PubMed ID: 22367657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levetiracetam as adjunctive therapy for refractory anxiety disorders.
    Kinrys G; Worthington JJ; Wygant L; Nery F; Reese H; Pollack MH
    J Clin Psychiatry; 2007 Jul; 68(7):1010-3. PubMed ID: 17685735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voluntary alcohol consumption and plasma beta-endorphin levels in alcohol preferring rats chronically treated with levetiracetam: a preliminary study.
    Zalewska-Kaszubska J; Bajer B; Czarnecka E; Dyr W; Gorska D
    Physiol Behav; 2011 Mar; 102(5):538-41. PubMed ID: 21187108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of levetiracetam for outpatient alcohol detoxification.
    Müller CA; Schäfer M; Schneider S; Heimann HM; Hinzpeter A; Volkmar K; Förg A; Heinz A; Hein J
    Pharmacopsychiatry; 2010 Jul; 43(5):184-9. PubMed ID: 20503149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial.
    Krebs M; Leopold K; Richter C; Kienast T; Hinzpeter A; Heinz A; Schaefer M
    J Clin Psychopharmacol; 2006 Jun; 26(3):347-9. PubMed ID: 16702910
    [No Abstract]   [Full Text] [Related]  

  • 11. Levetiracetam in the treatment of alcohol dependence: toward the end of the story?
    Le Strat Y
    Alcohol Clin Exp Res; 2012 Aug; 36(8):1309-10. PubMed ID: 22823576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piracetam and levetiracetam, two pyrrolidone derivatives, exert antidystonic activity in a hamster model of paroxysmal dystonia.
    Löscher W; Richter A
    Eur J Pharmacol; 2000 Mar; 391(3):251-4. PubMed ID: 10729365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: response to treatment with levetiracetam.
    Pollack MH; Jensen JE; Simon NM; Kaufman RE; Renshaw PF
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):739-43. PubMed ID: 18206286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between anxiety disorders and alcohol use disorders: a review of major perspectives and findings.
    Kushner MG; Abrams K; Borchardt C
    Clin Psychol Rev; 2000 Mar; 20(2):149-71. PubMed ID: 10721495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do clinical trials of treatment of alcohol dependence adequately enroll participants with co-occurring independent mood and anxiety disorders? An analysis of data from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC).
    Hoertel N; Falissard B; Humphreys K; Gorwood P; Seigneurie AS; Limosin F
    J Clin Psychiatry; 2014 Mar; 75(3):231-7. PubMed ID: 24569017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open-label nefazodone in patients with a major depressive episode and alcohol dependence.
    Brown ES; Bobadilla L; Nejtek VA; Perantie D; Dhillon H; Frol A
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Jun; 27(4):681-5. PubMed ID: 12787857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A complex relationship between co-occurring social anxiety and alcohol use disorders: what effect does treating social anxiety have on drinking?
    Thomas SE; Randall PK; Book SW; Randall CL
    Alcohol Clin Exp Res; 2008 Jan; 32(1):77-84. PubMed ID: 18028529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles.
    Genton P; Van Vleymen B
    Epileptic Disord; 2000 Jun; 2(2):99-105. PubMed ID: 10954241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients: a randomized trial.
    Richter C; Effenberger S; Bschor T; Bonnet U; Haasen C; Preuss UW; Heinz A; Förg A; Volkmar K; Glauner T; Schaefer M
    J Clin Psychopharmacol; 2012 Aug; 32(4):558-62. PubMed ID: 22722516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levetiracetam-induced parkinsonism in a Huntington disease patient.
    Zesiewicz TA; Sanchez-Ramos J; Sullivan KL; Hauser RA
    Clin Neuropharmacol; 2005; 28(4):188-90. PubMed ID: 16062099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.